Autoimmunity reviews最新文献

{"title":"Is it time for treat to target in antiphospholipid syndrome?","authors":"Savino Sciascia, Giuseppe Barilaro, Massimo Radin, Ricard Cervera, Dario Roccatello","doi":"10.1016/j.autrev.2024.103690","DOIUrl":"https://doi.org/10.1016/j.autrev.2024.103690","url":null,"abstract":"<p><p>A treat-to-target (T2T) approach aims to the identification of a clinically relevant therapeutic target and applies tight control (periodic visits at prespecified time-points and treatment adjustments) to achieve it with the goal of improving disease outcomes. The application of a T2T strategy appears to be less feasible in APS compared to other autoimmune diseases. This is primarily explicable by the disease's kaleidoscopic clinical presentation, along with the lack of a definitive tool (biomarkers or scoring system) to assess disease activity, making it complex to recognize a singular, effective therapeutic target for APS patients. Nevertheless, the conceptualization of T2T strategies should be considered a key objective when managing APS, aiming to achieve optimal disease control (including lowering the risk for recurrences), to reduce damage accumulation, and, ultimately, to enhance patients' quality of life.</p>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":" ","pages":"103690"},"PeriodicalIF":9.2,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142680697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing understanding of autoimmune disease-related interstitial lung disease (AD-ILD): A global perspective on research focus and future directions.","authors":"Ying-Xian Dong, Si-Cheng Zhou, Jie Tian","doi":"10.1016/j.autrev.2024.103697","DOIUrl":"https://doi.org/10.1016/j.autrev.2024.103697","url":null,"abstract":"<p><strong>Background: </strong>Interstitial lung disease (ILD), also known as autoimmune disease-associated ILD (AD-ILD), is a common complication of autoimmune diseases. Its rapid progression and worsening pulmonary fibrosis significantly increase the risk of mortality, leading to poor prognosis. Despite the considerable body of research in this field, there is a lack of bibliometric studies to address global research trends, key hotspots, and future directions.</p><p><strong>Methods: </strong>This study employed bibliometric methods to analyze 6456 publications related to this field from 1980 to 2024, using data extracted from the Web of Science (WOS) database. Visualization was conducted using tools such as VOSviewer, CiteSpace, and the bibliometrix R package.</p><p><strong>Results: </strong>The analysis encompassed contributions from 102 countries, 5957 institutions, and 25,003 researchers, published across 951 journals. Research output has surged since 2018, highlighting increased scholarly attention to the field. The United States produced the largest number of publications, with Mayo Clinic identified as the most prolific institution. The analysis revealed that Rheumatology and Annals of the Rheumatic Diseases had the highest publication volume and co-citation counts in the field, respectively. Dinesh Khanna was identified as the most prolific author, while V.D. Steen emerged as the most highly co-cited author. Keyword analysis highlighted that current AD-ILD research primarily focuses on optimizing diagnostic tools for specific autoimmune diseases, analyzing pathological types and risk factors, and exploring biomarkers and precision therapies. Thematic mapping underscored the need for future research to focus on AD-ILD mechanisms, specific antibodies, diagnostic markers, personalized treatments, and prognostic factors.</p><p><strong>Conclusion: </strong>This study provides a comprehensive bibliometric analysis of AD-ILD-related publications, uncovering global research trends and current hotspots while offering robust guidance for future research directions.</p>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":" ","pages":"103697"},"PeriodicalIF":9.2,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142680696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global research landscape on antiphospholipid syndrome and systemic lupus erythematosus: Trends, collaborations, and future directions.","authors":"Heng Bai, Jie Tian","doi":"10.1016/j.autrev.2024.103696","DOIUrl":"https://doi.org/10.1016/j.autrev.2024.103696","url":null,"abstract":"<p><strong>Background: </strong>Antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) are frequently studied together due to their close relationship. Despite significant research in this area, bibliometric studies addressing global research trends, key hotspots, and developmental trajectories are still lacking.</p><p><strong>Methods: </strong>This study employs bibliometric analysis to examine 2233 publications on APS and SLE from 1989 to 2024, sourced from the Web of Science (WOS) database. Visualization tools, such as the bibliometrix R package, CiteSpace, and VOSviewer, were utilized.</p><p><strong>Results: </strong>The analysis includes contributions from 9322 researchers across 2534 institutions in 91 countries, with publications spread across 585 journals. Research activity has increased substantially since 2015, reflecting the growing academic interest in the field. The United States led in publication volume, while Tel Aviv University produced the highest number of publications. Lupus had the highest number of both publications and citations. Yehuda Shoenfeld is the most prolific author, while Ronald A. Asherson is the most co-cited author. Keyword analysis revealed five major themes in APS and SLE research, covering thrombosis, cardiovascular diseases, immune response, pregnancy complications, and other connective tissue diseases. Thematic map emphasized the need for future research to focus on the immune mechanisms of antiphospholipid antibodies, thrombosis management, management of pregnancy complications, and interventions for neuropsychiatric symptoms.</p><p><strong>Conclusion: </strong>This study analyzes the literature on APS and SLE, revealing trends in the research of their immune mechanisms, thrombosis management, pregnancy complications, and neuropsychiatric symptoms, and providing strong guidance for future research directions.</p>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":" ","pages":"103696"},"PeriodicalIF":9.2,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142674767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of two pediatric patients with refractory systemic lupus erythematosus using CD19-targeted CAR T cells.","authors":"Xue He, Bin Hu, Yingzi Zhang, Fei Liu, Qiuyu Li, Chen Zheng, Junjie Shen, Zhi Yang, Jingjing Wang, Daqing Ma, Cheng Qian, Meiping Lu, Jianhua Mao","doi":"10.1016/j.autrev.2024.103692","DOIUrl":"https://doi.org/10.1016/j.autrev.2024.103692","url":null,"abstract":"<p><p>Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising strategy for treating autoimmune diseases, particularly in systemic lupus erythematosus (SLE). However, CAR T-cell therapy for pediatric patients with SLE remains unexplored. Herein, we present a compelling investigation of two pediatric patients with refractory SLE who underwent infusion of CD19-targeted CAR T-cell infusion. Patients 1 and 2 tolerated the CAR T-cell therapy well, which demonstrated remarkable efficacy after five and four months, respectively.</p>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":" ","pages":"103692"},"PeriodicalIF":9.2,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142674776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to \"Refining search and keyword strategies in autoimmune ear disease bibliometric studies\".","authors":"Yu-Chen Liu, Yi-Pin Yang, Yan-Xun Han, Bing-Yu Liang, Hai-Feng Pan, Ye-Hai Liu","doi":"10.1016/j.autrev.2024.103689","DOIUrl":"https://doi.org/10.1016/j.autrev.2024.103689","url":null,"abstract":"","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":" ","pages":"103689"},"PeriodicalIF":9.2,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142674772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of musculoskeletal ultrasound in difficult-to-treat RA: Insights from a systematic literature review.","authors":"Elisa Bellis, Federica Agugliaro, Claudia Garulli, Silvia Perrone, Gaetano Liperoti, Mariele Gatto, Annamaria Iagnocco","doi":"10.1016/j.autrev.2024.103694","DOIUrl":"10.1016/j.autrev.2024.103694","url":null,"abstract":"<p><p>Difficult-to-treat rheumatoid arthritis (D2TRA) identifies patients with insufficient response to biological or targeted-synthetic disease-modifying drugs (b/ts DMARDs), heralding a more severe phenotype. Musculoskeletal ultrasound (MSK-US) provides information on MSK inflammatory load and damage, being widely used in RA and inflammatory arthritides, yet the US patterns of D2TRA and correlation with clinical parameters have not been unanimously described so far. Here we investigated MSK-US patterns and their prognostic value in D2TRA through a systematic literature review (SLR) across MEDLINE (through PubMed), Scopus and Ovid (Embase) electronic databases. We initially retrieved 2365 papers; following the application of appropriate strings the number was lowered to 22. Among those, three papers fulfilled the required criteria. A total of 159 patients with D2TRA were analyzed. In comparison to non-D2TRA, D2TRA patients exhibited more extensive and severe synovitis, which correlated with higher disease activity scores and poorer treatment outcomes. Most US-affected joints belonged to hand and wrist. Grey-scale (GS) rather than power-Doppler (PD) synovitis score was consistently increased across D2TRA joints. Inclusion of US in recognition of D2TRA decreased the proportion of classifiable patients, identifying the true inflammatory D2T cases. The results of this SLR suggest that standardization of US phenotyping may aid the identification and stratification of D2TRA patients in clinical practice.</p>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":" ","pages":"103694"},"PeriodicalIF":9.2,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142666967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing the understanding of autoimmune/inflammatory syndrome induced by adjuvants (ASIA): Global research trends, key themes, and emerging frontiers.","authors":"Heng Bai, Jie Tian","doi":"10.1016/j.autrev.2024.103691","DOIUrl":"10.1016/j.autrev.2024.103691","url":null,"abstract":"<p><strong>Background: </strong>This study investigates global research on autoimmune/inflammatory syndrome induced by adjuvants (ASIA) to address gaps in disciplinary trends, research directions, and emerging topics, aiming to enhance understanding of ASIA's role in immune dysregulation and multi-system diseases.</p><p><strong>Methods: </strong>This study uses bibliometric methods, based on data from the Web of Science (WOS) database, to analyze 203 ASIA-related publications from 2011 to 2024. Analytical tools, including VOSviewer, CiteSpace, and the bibliometrix R package, were employed to identify key research directions and frontier topics.</p><p><strong>Results: </strong>Contributions from 40 countries, 318 institutions, and 824 researchers were analyzed, providing a global perspective on ASIA research. Israel contributed the highest publication volume, with Tel Aviv University being the most prolific contributor. Analysis showed that Immunologic Research published the most ASIA-related articles, whereas the Journal of Autoimmunity had the highest citation count. Keyword analysis identified six main research themes, including vaccine and adjuvant components, silicone implant-associated diseases, and connections between specific vaccines and autoimmune conditions. Thematic mapping highlighted key yet under-explored areas, such as immune responses to COVID-19 and HPV vaccines, and responses to specific adjuvants, offering insights into ASIA's complexity.</p><p><strong>Conclusion: </strong>This study provides a comprehensive analysis of ASIA's core themes and trends, highlighting key areas for future research, especially on the immune effects of vaccine adjuvants and implants. Although relying on a single data source, WOS's extensive coverage and citation tracking support the validity of these findings, laying a foundation for future ASIA research and clinical applications.</p>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":" ","pages":"103691"},"PeriodicalIF":9.2,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refining search and keyword strategies in autoimmune ear disease bibliometric studies","authors":"Heng Bai ,&nbsp;Jie Tian","doi":"10.1016/j.autrev.2024.103688","DOIUrl":"10.1016/j.autrev.2024.103688","url":null,"abstract":"<div><div>This study focuses on the search strategies used in bibliometric analyses within the field of autoimmune ear diseases, critically examining ways to improve search accuracy and relevance. Using the study by Liu et al. as an example, we found that the extensive search terms employed resulted in the inclusion of numerous irrelevant studies, weakening the specificity of the research findings. To address this issue, we propose a more precise search strategy using a combination of specific terms and wildcard symbols to ensure the search scope focuses on literature related to autoimmune ear diseases. Additionally, we recommend limiting search terms to titles, abstracts, and author keywords to reduce interference from unrelated literature. Moreover, we identify potential errors in keyword analysis caused by unmerged synonyms and suggest optimizing the accuracy of keyword co-occurrence analysis through synonym merging. This study aims to provide a more reliable methodological guide for future bibliometric analyses, thereby improving the quality and scientific rigor of research on autoimmune ear diseases.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"23 12","pages":"Article 103688"},"PeriodicalIF":9.2,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142613913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Harnessing the potential of CAR-T cell in lupus treatment: From theory to practice","authors":"Tamim Alsuliman ,&nbsp;Zora Marjanovic ,&nbsp;Doron Rimar ,&nbsp;Karin Tarte ,&nbsp;Tadej Avcin ,&nbsp;Melanie Hagen ,&nbsp;Georg Schett ,&nbsp;Dominique Farge","doi":"10.1016/j.autrev.2024.103687","DOIUrl":"10.1016/j.autrev.2024.103687","url":null,"abstract":"<div><div>Systemic Lupus Erythematosus (SLE) is a rare, heterogeneous, potentially life-threatening autoimmune disease. Presence of kidney or other major organ (brain, heart or lung) involvement are predictors of poor outcome and in a subset of patients resistant to 1st or 2nd line conventional treatment. The 10-year mortality remains around 10–15 %.</div><div>Chimeric Antigen Receptors (CAR) are molecules that allow to redirect the engineered immune cells towards specific target antigens and to simultaneously boost their activation. Following breakthrough results observed in the treatment of hematological malignancies, conventional CAR T-cell therapy has recently been applied to refractory SLE patients. Compared to the use of monoclonal antibodies, anti-CD19 CAR T-cells allow to achieve deeper depletion of autoreactive B cells, notably at site of inflamed tissues and lymphoid organs (i.e. lymph node), to suppress interferon signature and to restore the immune tolerance with the reemergence of naïve B-cells with a new repertoire.</div><div>All clinical data reported in SLE patients so far showed that autologous anti-CD19 CAR T-cell treatment allowed impressive short- and longer-term resolution of lupus nephritis and other severe disease-related manifestations, without major toxicities and only mild cytokine-release syndrome. These clinical effects persisted after B-cell reconstitution and were associated with normalization of double-stranded DNA antibodies and complement levels in drug-free patients until three years after the procedure. Overall, these pioneering experiences show unique clinical and immunological response to CAR T-cell therapy in SLE, and the need for extended follow-up to determine its long-term efficacy.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"23 12","pages":"Article 103687"},"PeriodicalIF":9.2,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142613912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autoimmunity, a relevant exclusion criterion in the development of mRNA-based compounds: A systematic review of clinical trials registries","authors":"Larisa Pinte ,&nbsp;Alina Dima ,&nbsp;Anamaria Draghici ,&nbsp;Maria Caraghiulea ,&nbsp;Ioana Andreea Zamfir-Gradinaru ,&nbsp;Cristian Baicus","doi":"10.1016/j.autrev.2024.103670","DOIUrl":"10.1016/j.autrev.2024.103670","url":null,"abstract":"<div><h3>Background</h3><div>Messenger RNA (mRNA) -based compounds have been lately developed as one of the most promising treatment alternatives in a wide range of pathologies, especially cancers and infectious diseases.</div></div><div><h3>Aim</h3><div>To review the current research landscape on mRNA-based compounds, with a focus on the inclusion criteria used for participants with autoimmune diseases and/or under immunosuppressive treatments.</div></div><div><h3>Methods</h3><div>We conducted a comprehensive search based on PICO framework specifically formulated, throughout the most important clinical trial registries: WHO International Clinical Trials Registry Platform (ICTRP) portal, ClinicalTrials.gov, and the Cochrane Central Register of Controlled Trials (CENTRAL), as well as in the Pfizer-BioNTech and Moderna official websites.</div><div>Data extraction followed the CONSORT checklist, focusing on identifying the specific exclusion criteria for individuals with autoimmune diseases and those undergoing various immunosuppressive treatments, including daily dosages, treatment length, and required cessation periods before enrollment.</div><div>We performed descriptive and comparative analyses using statistical tests where applicable.</div><div>This review followed PRISMA guidelines, and the protocol was registered on PROSPERO (CRD42024544811).</div></div><div><h3>Results</h3><div>Out of 2818 study protocols identified, 608 met the eligibility criteria, the vast majority (96.9 %) focusing on non-replicating RNA.</div><div>Most targeted were infectious diseases (66.6 %), primarily COVID-19 (51.3 %), followed by cancers (29.1 %), and other conditions (4.3 %).</div><div>Having an autoimmune disease was used as an exclusion criterion in 60.8 % of trials; higher exclusion rates were observed in studies designed for cancers when compared to those assessing infections or other pathologies (79.1 % vs. 55.3 % vs. 23.1 %, <em>p</em> &lt; 0.001), as well as in those using cell-based when compared to non-cell delivery systems (79.2 % vs. 57.2 %, p &lt; 0.001).</div><div>Further, participants under immunosuppressive treatments were excluded from 77.5 % of the trials, primarily due to corticosteroid use. There is considerable variability in exclusion criteria related to immunosuppressive treatment length and cessation time prior enrollment, as well as in the daily corticosteroid dosage.</div></div><div><h3>Conclusion</h3><div>To the best of our knowledge, this is the first review to document the ongoing research designed for mRNA-based compounds. This work highlights the underrepresentation of patients with autoimmune diseases and those on immunosuppressive treatments in clinical trials assessing mRNA-based compounds.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"23 12","pages":"Article 103670"},"PeriodicalIF":9.2,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142613946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}